Show simple item record

dc.contributor.authorDomenech, Mirian 
dc.contributor.authorDamián, Diana
dc.contributor.authorArdanuy, Carmen
dc.contributor.authorLiñares, Josefina
dc.contributor.authorFenoll, Asuncion 
dc.contributor.authorGarcía, Ernesto
dc.date.accessioned2018-12-27T11:44:27Z
dc.date.available2018-12-27T11:44:27Z
dc.date.issued2015-04-30
dc.identifier.citationPLoS One. 2015 Apr 30;10(4):e0125636es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6968
dc.description.abstractBACKGROUND: Since the use of pneumococcal conjugate vaccines PCV7 and PCV13 in children became widespread, invasive pneumococcal disease (IPD) has dramatically decreased. Nevertheless, there has been a rise in incidence of Streptococcus pneumoniae non-vaccine serotypes (NVT) colonising the human nasopharynx. Nasopharyngeal colonisation, an essential step in the development of S. pneumoniae-induced IPD, is associated with biofilm formation. Although the capsule is the main pneumococcal virulence factor, the formation of pneumococcal biofilms might, in fact, be limited by the presence of capsular polysaccharide (CPS). METHODOLOGY/PRINCIPAL FINDINGS: We used clinical isolates of 16 emerging, non-PCV13 serotypes as well as isogenic transformants of the same serotypes. The biofilm formation capacity of isogenic transformants expressing CPSs from NVT was evaluated in vitro to ascertain whether this trait can be used to predict the emergence of NVT. Fourteen out of 16 NVT analysed were not good biofilm formers, presumably because of the presence of CPS. In contrast, serotypes 11A and 35B formed ≥45% of the biofilm produced by the non-encapsulated M11 strain. CONCLUSIONS/SIGNIFICANCE: This study suggest that emerging, NVT serotypes 11A and 35B deserve a close surveillance.es_ES
dc.description.sponsorshipThis work was supported by grants from the Ministerio de Economía y Competi-tividad (SAF2012-39444-C02-01/02 and PI11/0763). CIBER de Enfermedades Respiratorias (CIBERES) is an initiative of Instituto de Salud Carlos III. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshBiofilms es_ES
dc.subject.meshPneumococcal Vaccines es_ES
dc.subject.meshPolysaccharides, Bacterial es_ES
dc.subject.meshSerogroup es_ES
dc.subject.meshStreptococcus pneumoniae es_ES
dc.titleEmerging, Non-PCV13 Serotypes 11A and 35B of Streptococcus pneumoniae Show High Potential for Biofilm Formation In Vitroes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID25927917es_ES
dc.format.volume10es_ES
dc.format.number4es_ES
dc.format.pagee0125636es_ES
dc.identifier.doi10.1371/journal.pone.0125636es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderInstituto de Salud Carlos III 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1932-6203es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0125636es_ES
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2012-39444-C02-01/02es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/0763es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional